Hepatitis C: Move over interferon

Nature Biotechnology

Volumn 29, Issue 11, 2011, Pages 963-966

  Garber, Ken ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABT 072; ABT 450; ALPHA INTERFERON; ANTIVIRUS AGENT; BI 201335; BI 2071287; BMS 790052; BOCEPREVIR; DANOPREVIR; GS 5885; GS 9451; MERICITABINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PSI 7977; PSI 938; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG POTENCY; HEPATITIS C; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG CONTAMINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; PROTEASE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 80755159044     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2031     Document Type: Article

References (10)

1. Kwong, A.D. et al. Nat. Biotechnol. 29, 993-1003. (2011).
2. Lok, A. et al. J. Hepatol. 54, Suppl. 1, S536, abstract 1356 (2011).
3. Fried, M. et al. AASLD annual meeting abstract LB-5 (2011).
4. Garber, K. Nat. Biotechnol. 25, 1379-1381 (2007).
5. Gao, M. et al. Nature 465, 96-100 (2010).
6. Tellinghuisen, T.L. et al. Nature 435, 374-379 (2005).
7. Chayama, K. et al. AASLD annual meeting abstract LB-4 (2011).
8. Ge, D. et al. Nature 461, 399-401 (2009).
9. Thomas, D.L. et al. Nature 461, 798-801 (2009).
10. Murray, C.L. & Rice, C.M. Nature 465, 42-44 (2010).